Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Nps Pharmaceuticals Inc patents


Recent patent applications related to Nps Pharmaceuticals Inc. Nps Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Nps Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Nps Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "N" | Nps Pharmaceuticals Inc-related inventors


Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020982

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020981

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020980

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020979

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020978

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020977

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020976

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020975

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020974

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020973

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020972

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020971

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020970

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020969

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020968

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020967

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020966

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc

01/26/17 / #20170020965

Treatment of short bowel syndrome patients with colon-in-continuity

Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a glp-2 receptor agonist, such as teduglutide.. . ... Nps Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Nps Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Nps Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###